Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

ABSTRACT: The aim of this study is to investigate the efficacy, safety, and survival benefit of etoposide plus cisplatin and irinotecan plus cisplatin in first-line therapy of non-primary pancreatic metastatic and/or unresectable gastrointestinal neuroendocrine tumor G3 type. In addition, the investigators will explore the resistance mechanisms of gastrointestinal neuroendocrine tumor G3, and screen out biomarkers that can predict the efficacy of chemotherapy.

DISEASE(S): Neuroendocrine Tumors,Gastrointestinal Neuroendocrine Tumor,Pancreatic Neoplasms,Stomach Neoplasms,Intestinal Neoplasms

PROVIDER: 2306573 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Mutation in H82 P0,P1,P2,P3,P4 tumors

Project description:Detect the mutation in tumors with etoposide plus cisplatin treatment

2021-12-01 | GSE160239 | GEO

Gene expression in H82R cells

Project description:H82R cells was derived from H82 P4 tumors and was resistant to etoposide plus cisplatin

2021-12-01 | GSE160240 | GEO

Tumor heterogeneity underlies differential cisplatin sensitivity in mouse models of small cell lung cancer

Project description:SCLC is the most aggressive subtype of lung cancer characterized by a remarkable response to chemotherapy followed by development of resistance. Mechanisms of initial sensitivity and of subsequent resistance are not understood. Here we highlight a broad tumor heterogeneity in mouse models of SCLC, which includes a CDH1 high primary cisplatin-resistant peripheral neuroendocrine lesion with unique metabolic and structural profile. Cisplatin treatment preferentially eliminates CDH1 negative secondary tumor leaving behind CDH1 high primary lesions, thus revealing a striking differential response. We profile global protein and messenger RNA levels in vehicle and cisplatin treated lung tumor populations and find a marked reduction in proliferation and a pronounced metabolic shift following cisplatin-treatment. Our proteo-transcriptomic analysis gives insight into gene expression alterations that characterize cisplatin resistance and uncovers potential novel targets to overcome resistance of distinct populations. SCLC tumors in the mouse show heterogeneity which appears, as might be the case in humans, to be one of the underlying mechanisms of differential sensitivity to cisplatin.

2019-11-12 | PXD010680 | Pride

Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer [scRNA-seq]

Project description:We analyzed chromatin accessibility, scATAC-seq and RNA-seq across neuroendocrine carcinomas from distinct anatomic origins including Merkel cell carcinomas, neuroendocrine prostate cancer, small cell lung cancer and gastrointestinal NECs.

2024-03-27 | GSE262624 | GEO

Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer [scATAC-seq]

2024-03-27 | GSE262623 | GEO

Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer [ChIP-seq]

Project description:We analyzed chromatin accessibility, ChIP-seq and RNA-seq across neuroendocrine carcinomas from distinct anatomic origins including Merkel cell carcinomas, neuroendocrine prostate cancer, small cell lung cancer and gastrointestinal NECs.

2021-08-12 | GSE156290 | GEO

Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer [RNA-seq]

2021-08-12 | GSE156289 | GEO

Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer [ATAC-seq]

2021-08-12 | GSE156291 | GEO

Gene expression data of human gastric tumors

Project description:Tumors of advanced gastric cancer patients were biopsied and subjected to gene expression profiling using the Affymetrix Human Genome U133 Plus 2.0 Arrays. Patients were then segregated into G1, G2 or G3 groups based on their tumor genomic profiles. Patients in the G1 and G3 cohorts were assigned SOX (oxaliplatin plus S-1) chemotherapy whereas those in the G2 cohort were given SP (cisplatin plus S-1) regimen. This bench-to-bedside effort indicated the feasibility of using molecular profiling to tailor treatment for advanced gastric cancer.

2018-07-31 | GSE100935 | GEO

A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3

Project description:To assess the primary effects and safety of Anlotinib in patients with Gastroenteropancreatic Neuroendocrine Tumor G3.

| 2267764 | ecrin-mdr-crc